SCHEMBL9908323

SCHEMBL9908323

O=S(=O)(c1ccccc1)N1CCc2cc(I)cnc21

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.48
HTR6 P50406 8/20 0.44
DRD3 P35462 7/20 0.44
HRH3 Q9Y5N1 1/20 0.44
PKM P14618 3/20 0.43
JAK2 O60674 2/20 0.43
DRD2 P14416 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
RORC P51449 1/20 0.42
NR1H3 Q13133 1/20 0.42
AKR1C3 P42330 1/20 0.41
AKR1C1 Q04828 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13005132 0.84 CYP11B1 (0.48) CYP11B1HTR6DRD3HRH3PKM
SCHEMBL3352898 0.84 CYP11B1 (0.48) CYP11B1HTR6DRD3HRH3PKM
SCHEMBL17165146 0.78 HDAC1 (0.53) CYP11B1HTR6DRD3HRH3ALDH1A1
SCHEMBL17165145 0.78 HDAC1 (0.53) CYP11B1HTR6DRD3HRH3ALDH1A1
SCHEMBL21779271 0.77 HDAC3 (0.61) CYP11B1HTR6DRD3HRH3PKM
SCHEMBL18549261 0.74 HDAC1 (0.69)
SCHEMBL17173412 0.74 HDAC1 (0.69)
SCHEMBL13217157 0.74 MMP2 (0.45) CYP11B1PKMJAK2ALDH1A1MCOLN3
SCHEMBL17165071 0.74 CYP11B1 (0.52) CYP11B1PKMJAK2ALDH1A1MCOLN3
SCHEMBL17173847 0.74 HDAC1 (0.52) CYP11B1PKMALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198273-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2012-06-12 US disclosed
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor PLEXXIKON, INC. 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286142-A1 Compounds and Methods for Kinase Modulation, and Indications Therefor BRAF, ARAF, RAF1 CYP11B1 618/4885HTR6 3085/4885DRD3 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.